Eli Lilly: positive results for lasmiditan.
(CercleFinance.com) - Eli Lilly has announced that lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, met its primary endpoint in SPARTAN, a second Phase 3 study.
At two hours following the first dose, a greater percentage of patients treated with lasmiditan were migraine pain-free compared to placebo. These results were statistically significant across all three studied doses (50 mg, 100 mg and 200 mg).
There was also a statistically significant reduction seen in the symptoms considered to be most troublesome (nausea, sensitivity to noise or light) by patients - again relative to placebo.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
At two hours following the first dose, a greater percentage of patients treated with lasmiditan were migraine pain-free compared to placebo. These results were statistically significant across all three studied doses (50 mg, 100 mg and 200 mg).
There was also a statistically significant reduction seen in the symptoms considered to be most troublesome (nausea, sensitivity to noise or light) by patients - again relative to placebo.
Copyright (c) 2017 CercleFinance.com. All rights reserved.